Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

1. Clopidogrel

Clopidogrel Top results for clopidogrel - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for clopidogrel The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

2. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la Full Text available with Trip Pro

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.GLOBAL LEADERS was a randomised (...) , open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary

2018 Lancet Controlled trial quality: predicted high

3. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy CPIC UPdate nature publishing group Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss- of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel (...) , diabetes mellitus, obesity, smoking, and concomitant use of other drugs that may influence clopidogrel efficacy and clinical decision making. The CPIC of the National Institutes of Health’s Pharmacogenomics Research Network and PharmGKB develops peer-reviewed gene/drug guidelines that are published and updated on www.pharmgkb. org every 2 years or as needed based on significant developments in the field. 2 FOCUSED LITERATURE REVIEW A systematic literature review was conducted on CYP2C19 geno- type

2013 Clinical Pharmacogenetics Implementation Consortium

4. Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases

Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases 1 - Final report - [Commission No. A04-01A] 1 Publication date of the English translation: 04 October 2006. This translation is based on the German final report “Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen” (Version 1.0, 30 June 2006). Please note: The translation (...) is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Final report A04-01A: Clopidogrel versus ASA for secondary prevention of vascular diseases 2 Topic: Evaluation of the benefits and harms of clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases Contracting agency: Federal Joint Committee (Gemeinsamer Bundesausschuss) Date of Commission: 15 December 2004 Internal

2006 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. (Abstract)

Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. Proton-pump inhibitors (PPIs) are often prescribed to patients receiving dual antiplatelet therapy (DAPT). However, this class of medication, especially omeprazole, has been associated with a reduction in clopidogrel efficacy, leading many clinicians to substitute omeprazole with ranitidine.Our objective was to compare the antiplatelet effect (...) of clopidogrel before and after the addition of omeprazole or ranitidine.We measured platelet aggregability at baseline and after 1 week of clopidogrel 75 mg daily. Subjects were then randomized in a double-blinded, double-dummy fashion to omeprazole 20 mg twice daily (bid) or ranitidine 150 mg bid. We repeated aggregability tests after 1 additional week, using VerifyNow P2Y12™ (Accumetrics; San Diego, CA, USA), depicting aggregability as percent inhibition of platelet aggregation (IPA).We enrolled 41

2016 American journal of cardiovascular drugs : drugs, devices, and other interventions Controlled trial quality: predicted high

6. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions CADTH Technology Report Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary (...) Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses Issue 133 November 2010Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Cite as: Banerjee S, Brown A, McGahan L, Asakawa K, Hutton B, Clark M, Severn M, Sharma M, Cox JL. Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome

2011 EvidenceUpdates

7. Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety

Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drug Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of proton pump inhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. The evidence suggests that there are still some serious safety risks associated with the use of proton pump inhibitors (PPIs) with clopidogrel antiplatelet

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Clopidogrel/Acetylsalicylic acid Teva

Clopidogrel/Acetylsalicylic acid Teva 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 26 June 2014 EMA/CHMP/333195/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Clopidogrel / Acetylsalicylic acid (...) Teva International non-proprietary name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/002272/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised Assessment report EMA/502333/2014 Page 2/43 Table of contents 1. Background information on the procedure 6 2. Scientific discussion 8 2.1. Quality aspects 8 2.2. Non-clinical aspects 13 2.3. Clinical aspects 19 2.4. Clinical efficacy 28

2014 European Medicines Agency - EPARs

9. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. Full Text available with Trip Pro

Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. The bleeding safety of ticagrelor in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy remains uncertain.To evaluate the short-term safety of ticagrelor when compared with clopidogrel in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy.We conducted a multicenter, randomized, open-label (...) with blinded end point adjudication trial that enrolled 3799 patients (younger than 75 years) with ST-segment elevation myocardial infarction receiving fibrinolytic therapy in 152 sites from 10 countries from November 2015 through November 2017. The prespecified upper boundary for noninferiority for bleeding was an absolute margin of 1.0%.Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300-mg to 600-mg loading dose, 75 mg daily thereafter

2018 JAMA cardiology Controlled trial quality: predicted high

10. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Full Text available with Trip Pro

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus (...) rhythm.This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of

2009 EvidenceUpdates Controlled trial quality: predicted high

11. Evaluation of the effectiveness of platelet function analysis-guided aspirin and/or clopidogrel therapy in patients with transient ischaemic attack or ischaemic stroke in preventing secondary stroke: a systematic review and meta-analysis

Evaluation of the effectiveness of platelet function analysis-guided aspirin and/or clopidogrel therapy in patients with transient ischaemic attack or ischaemic stroke in preventing secondary stroke: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2019 PROSPERO

12. Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines

Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions While combination therapy with clopidogrel and ASA remains the basis

2012 Health Technology Assessment (HTA) Database.

13. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. Full Text available with Trip Pro

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a reduction in the risk of recurrent stroke. We tested this combination in an international population.In a randomized trial, we assigned patients with minor (...) ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. The dose of aspirin in each group was selected by the site investigator. The primary efficacy outcome in a time-to-event analysis was the risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event

2018 NEJM Controlled trial quality: predicted high

14. Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2018 Clinical Trials

15. Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarct

Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarct Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with … Article Text Therapeutics Randomised controlled trial Percutaneous coronary intervention for acute coronary syndromes: no difference

2011 Evidence-Based Medicine

16. Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes

Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacogenetics of Clopidogrel (...) by (Responsible Party): Diego Ardissino, Azienda Ospedaliero-Universitaria di Parma Study Details Study Description Go to Brief Summary: The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndromes, and is therefore one of the most frequently prescribed drugs worldwide. Accumulating data suggest that the response to clopidogrel is characterised by significant inter-patient variability in the degree of platelet inhibition and the risk

2017 Clinical Trials

17. Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. (Abstract)

Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. Among patients at high risk for or with established cardiovascular disease (ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary stent), is the addition of clopidogrel to aspirin associated with lower risk of mortality and cardiovascular events compared with aspirin alone?Clopidogrel plus aspirin is associated

2018 JAMA

18. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol versus Standard Dual Anti-platelet in Patients with High Post-Treatment Platelet Reactivity: Results of the CREATIVE Trial (Clopidogrel Response Evaluation and AnTi-platelet InterV Full Text available with Trip Pro

Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol versus Standard Dual Anti-platelet in Patients with High Post-Treatment Platelet Reactivity: Results of the CREATIVE Trial (Clopidogrel Response Evaluation and AnTi-platelet InterV Patients undergoing percutaneous coronary intervention react differently to antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of cardiac ischemic events. The goal of this study is to conduct a head-to-head (...) comparison of the safety and effectiveness of intensified antiplatelet therapies (either double-dose clopidogrel [DOUBLE] or adjunctive cilostazol [TRIPLE]) and conventional strategy (STANDARD) in patients after percutaneous coronary intervention.In this single-center, randomized, controlled trial, we used thromboelastography, a platelet function test, to select 1078 patients undergoing percutaneous coronary intervention at high thrombotic risk and compared the intensified antiplatelet therapies

2018 EvidenceUpdates

19. What is the evidence for aspirin v clopidogrel for stroke prevention after TIA? how much better is clopidogrel? If a patient really wants to stay on esomeprazole for their stomach, is it better to s

What is the evidence for aspirin v clopidogrel for stroke prevention after TIA? how much better is clopidogrel? If a patient really wants to stay on esomeprazole for their stomach, is it better to s What is the evidence for aspirin v clopidogrel for stroke prevention after TIA? how much better is clopidogrel? If a patient really wants to stay on esomeprazole for their stomach, is it better to switch to aspirin or stay on clopidogrel for stroke prevention following TIA. Thanks. - Trip Database (...) of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What is the evidence for aspirin v clopidogrel for stroke prevention after TIA? how much better is clopidogrel? If a patient really wants to stay on esomeprazole for their stomach, is it better to switch to aspirin or stay on clopidogrel for stroke prevention following TIA. Thanks. The CKS guideline on Stroke and TIA (1) has a clinical scenario on drug treatments for secondary prevention following a confirmed

2014 TRIP Answers

20. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi Full Text available with Trip Pro

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death.Few data (...) exist on the optimal antithrombotic therapy following TAVR.This was a randomized controlled trial comparing aspirin (80 to 100 mg/day) plus clopidogrel (75 mg/day) (dual antiplatelet therapy [DAPT]) versus aspirin alone (single-antiplatelet therapy [SAPT]) in patients undergoing TAVR with a balloon-expandable valve. The primary endpoint was the occurrence of death, myocardial infarction (MI), stroke or transient ischemic attack, or major or life-threatening bleeding (according to Valve Academic

2017 JACC. Cardiovascular interventions Controlled trial quality: predicted high